John Johnson, Director at Xeris Biopharma Holdings, Inc. (XERS), sold 15,000 shares at $6.09 ($91K) on 2026-06-04, disclosed to the SEC on 2026-06-05.
Scheduled sale ($91k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AXGN | SELL | 2025-12-10 | $2.8M | — | Filing → |
| XERS | SELL | 2025-08-15 | $787K | — | Filing → |
| AXGN | SELL | 2025-06-11 | $43K | — | Filing → |